Also known as Otezla.
Phase 3 secondary data show ~75% scalp and ~70% palmoplantar clearance at week 16; significant nail improvement; responses sustained to week 24; common AEs: URTI, nasopharyngitis, acne.
APEX Phase‑3b: in biologic‑naïve PsA patients, 24‑week results met ACR20 and significantly inhibited structural joint damage vs placebo; placebo switchers had 57% less radiographic progression to Week 48; safety unchanged.
Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience
Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.
